Welcome to our dedicated page for Regulus Therapeu news (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeu stock.
Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company headquartered in San Diego, California, that focuses on the discovery and development of medicines targeting microRNAs. Its recent news flow has centered on its lead candidate, farabursen (RGLS8429), a next generation oligonucleotide designed to inhibit miR‑17 and preferentially target the kidney for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
News updates for RGLS commonly include clinical trial milestones for farabursen, such as topline data from the Phase 1b multiple-ascending dose (MAD) study in adult ADPKD patients. Regulus has reported mechanistic responses based on urinary polycystins 1 and 2 (PC1 and PC2), exploratory findings on height-adjusted total kidney volume (htTKV), and safety and tolerability data from multiple cohorts, including a fixed 300 mg dose regimen. Company releases also describe interactions with the U.S. Food and Drug Administration (FDA), including an End-of-Phase 1 meeting and alignment on key elements of a planned single pivotal Phase 3 trial with htTKV and eGFR endpoints.
Another major theme in Regulus news is corporate and transaction activity. The company announced an Agreement and Plan of Merger with Novartis AG, under which Novartis, through a subsidiary, launched a tender offer to acquire all outstanding Regulus shares for cash plus a non-tradeable contingent value right (CVR) tied to a regulatory milestone for farabursen. Subsequent disclosures report the successful completion of the tender offer and the closing of the merger, after which Regulus became an indirect wholly owned subsidiary of Novartis.
Additional RGLS news items include financial results for recent quarters and years, updates on cash runway expectations, and participation in healthcare and biotech investment conferences where management discusses the farabursen program and the company’s microRNA-targeting platform. For investors and researchers, the RGLS news page provides a consolidated view of clinical progress, regulatory interactions, transaction developments, and financial updates related to Regulus Therapeutics and its microRNA-based therapeutic strategy.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced that Jay Hagan, President and CEO, will present at the H.C. Wainwright Virtual BioConnect Conference from January 10-13, 2022. An on-demand webcast will be available on January 10, 2022, at 7:00 a.m. ET. The presentation will focus on the company's innovative medicines targeting microRNAs. The webcast will be accessible via the investor relations section of their website, with a replay archived for 30 days.
Regulus, headquartered in San Diego, CA, has developed a robust pipeline and holds significant intellectual property in the microRNA domain.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the appointment of Mohammad Ahmadian, Ph.D., as Vice President of Chemistry and Pharmaceutical Development. Dr. Ahmadian brings over 20 years of experience in drug discovery, particularly in oligonucleotides, and will oversee the R&D of drug candidates, including RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD). He was previously at Kinovate Life Sciences, focusing on operations and quality control. Alongside his role, he received an option to purchase 200,000 shares at $0.36 each, vesting over four years.
Regulus Therapeutics (Nasdaq: RGLS) presented at the first annual Rare & Genetic Kidney Disease Drug Development Summit, highlighting its research on microRNAs (miRs) for treating genetic kidney diseases. The Company reported a 58% and 38% increase in biomarkers PC1 and PC2 in ADPKD patients following treatment with its drug RGLS4326. Regulus is prioritizing its second-generation miR-17 inhibitor RGLS8429, with a pre-IND meeting scheduled with the FDA in December 2021, aiming for IND submission by Q2 2022.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the successful completion of a private equity placement, raising approximately $34.6 million. This was achieved by selling about 58.9 million shares of common stock at $0.36 per share and 3.7 million shares of non-voting convertible preferred stock at $3.60 per share. The proceeds will support non-clinical and clinical development activities. The financing was facilitated by SVB Leerink as the lead placement agent and H.C. Wainwright as co-placement agent.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced a private placement financing led by Federated Hermes Kaufmann Funds and New Enterprise Associates, aiming to raise approximately $34.6 million. This financing involves the purchase of about 58.9 million shares of common stock at $0.36 per share and 3.7 million shares of non-voting Class A-4 convertible preferred stock at $3.60 per share, convertible into common stock. The closing is expected around November 30, 2021, pending customary conditions.
Regulus Therapeutics (Nasdaq: RGLS) reported its Q3 2021 financial results on November 10, 2021. The company had $35.8 million in cash as of September 30, 2021, with net losses of $8.6 million for the quarter. Regulus is focusing on the development of RGLS8429 for ADPKD, having discontinued RGLS4326 due to its limitations. A pre-IND meeting with the FDA is expected in December 2021, with clinical development anticipated in Q2 2022. The company reported increased R&D expenses of $5.9 million for the quarter, up from $4.0 million the previous year.
Regulus Therapeutics Inc. (RGLS) announced it will report its financial results for Q3 2021 on November 10, 2021, after market close. A conference call and webcast will also be held on the same day at 5:00 PM EDT. The call can be accessed domestically at (877) 257-8599 or internationally at (970) 315-0459, with a replay option available. The company focuses on microRNA-targeted medicines and notes potential risks affecting its business, including impacts from the COVID-19 pandemic.
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced a strategic focus on RGLS8429 for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). Following the completion of IND-enabling toxicity studies, the firm plans to submit an Investigational New Drug (IND) application and has scheduled a Phase 1 study in Q2 2022, subject to FDA approval. The decision stems from recent data suggesting RGLS8429's improved pharmacological profile and absence of negative CNS effects previously seen with RGLS4326. Initial biomarker data is expected in early 2023.
Regulus Therapeutics (Nasdaq: RGLS) announced that its director, David Baltimore, Ph.D., received the 2021 Lasker-Koshland Special Achievement Award for his significant contributions to virology, immunology, and cancer. This prestigious award celebrates advances in medical science and highlights the importance of public support for research. The CEO, Jay Hagan, praised Dr. Baltimore's extensive work and its influence on biotechnology and public health, including his role during the AIDS crisis. Regulus continues to benefit from his guidance in advancing its pipeline of microRNA therapeutics.
Regulus Therapeutics (Nasdaq: RGLS), a biopharmaceutical company specializing in microRNA therapeutics, announced that its CEO, Jay Hagan, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET. The presentation will be accessible via an on-demand webcast available on their investor relations website. A replay will be archived for 30 days. Regulus focuses on developing innovative medicines and holds a strong intellectual property portfolio in the microRNA sector.
FAQ
What is the current stock price of Regulus Therapeu (RGLS)?
What is the market cap of Regulus Therapeu (RGLS)?
